UniQure out-licenses hemophilia B gene therapy in deal valued up to ~$2.1B

UniQure out-licenses hemophilia B gene therapy in deal valued up to ~$2.1B

Submitted by admin on June 24, 2020 - 11:29pm
Source: 
Seeking Alpha
News Tags: 
uniQure
CSL
hemophilia B
etranacogene dezaparvovec
Headline: 
UniQure out-licenses hemophilia B gene therapy in deal valued up to ~$2.1B
snippet: 

UniQure (NASDAQ:QURE) inks an agreement with CSL Limited (OTCPK:CMXHF) unit CSL Behring granting the latter global rights to gene therapy etranacogene dezaparvovec for the treatment of hemophilia B.

Do Not Allow Advertisers to Use My Personal information